 Emmaus Life Sciences Inc OTCQX:EMMA announced that it has entered into an agreement with Asembia to provide expanded support services and simplify access to Endari the companys prescription L-glutamine oral powder for the treatment of sickle cell disease. The Torrance, California-based company said that Asembia will provide a single point of contact for benefits investigation, financial and co-pay assistance, as well as patient and provider education. 